| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CH5424802 | GDSC1000 | pan-cancer | AAC | 0.46 | 6e-45 |
| mRNA | XMD14-99 | GDSC1000 | pan-cancer | AAC | 0.3 | 7e-20 |
| mRNA | XMD15-27 | GDSC1000 | pan-cancer | AAC | 0.31 | 1e-18 |
| mRNA | MPS-1-IN-1 | GDSC1000 | pan-cancer | AAC | 0.28 | 1e-18 |
| mRNA | TAE684 | CTRPv2 | pan-cancer | AAC | 0.27 | 2e-15 |
| mRNA | HG-5-88-01 | GDSC1000 | pan-cancer | AAC | 0.32 | 2e-12 |
| mRNA | TAE684 | GDSC1000 | pan-cancer | AAC | 0.35 | 2e-11 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.21 | 1e-10 |
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | 0.33 | 1e-10 |
| mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | 0.21 | 1e-09 |